Viridian Therapeutics Enters Material Definitive Agreement
Ticker: VRDN · Form: 8-K · Filed: Oct 20, 2025 · CIK: 1590750
Sentiment: neutral
Topics: material-agreement, definitive-agreement
TL;DR
Viridian Therapeutics just signed a big deal, details TBD.
AI Summary
Viridian Therapeutics, Inc. entered into a Material Definitive Agreement on October 17, 2025. The filing does not specify the other party or the nature of the agreement, but it is classified under Item Information as an 'Entry into a Material Definitive Agreement'.
Why It Matters
This filing indicates a significant new contract or partnership for Viridian Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The nature and terms of the material definitive agreement are not disclosed, creating uncertainty about its impact.
Key Numbers
- 001-36483 — SEC File Number (Identifies the company's filing history with the SEC.)
- 47-1187261 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- October 17, 2025 (date) — Date of earliest event reported
- October 20, 2025 (date) — Filing Date
- Miragen Therapeutics, Inc. (company) — Former Company Name
- Signal Genetics, Inc. (company) — Former Company Name
FAQ
What is the nature of the Material Definitive Agreement entered into by Viridian Therapeutics?
The filing does not specify the nature of the Material Definitive Agreement, only that it was entered into on October 17, 2025.
Who is the other party to the Material Definitive Agreement?
The filing does not disclose the identity of the other party involved in the Material Definitive Agreement.
What is the effective date of the Material Definitive Agreement?
The earliest event reported, which is the entry into the Material Definitive Agreement, is dated October 17, 2025.
What is Viridian Therapeutics' primary business sector?
Viridian Therapeutics, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Has Viridian Therapeutics undergone name changes in the past?
Yes, Viridian Therapeutics was formerly known as Miragen Therapeutics, Inc. (name change on 20170213) and prior to that, Signal Genetics, Inc. (name change on 20140710).
Filing Stats: 1,555 words · 6 min read · ~5 pages · Grade level 13.1 · Accepted 2025-10-20 07:42:37
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value VRDN The Nasdaq Stock Mar
- $300 million — from the Company in exchange for up to $300 million in consideration consisting of: (a) $55
- $55 million — ion in consideration consisting of: (a) $55 million that was paid on the signing date; (b)
- $25 million — that was paid on the signing date; (b) $25 million that is payable following the achieveme
- $75 million — L-2, on or before a specified date; (c) $75 million that is payable following receipt of ma
- $15 million — DA") on or before a specified date; (d) $15 million that is payable if the events set forth
- $50 million — egoing clauses (b) and (c) are met; (e) $50 million that is payable following receipt of ma
- $1.1 billion — certain products equal to or exceeding $1.1 billion on or before a specified date; and (g)
- $30 million — a specified date; and (g) an additional $30 million that may be payable to the Company at a
- $600 m — nual U.S. net sales up to and including $600 million, which royalties could increase t
- $600 million — ii) 0.8% of annual U.S. net sales above $600 million and up to and including $900 million, (
- $900 m — ve $600 million and up to and including $900 million, (iii) 0.25% of annual U.S. net s
- $900 million — i) 0.25% of annual U.S. net sales above $900 million and up to $2 billion, and (iv) no royal
- $2 b — net sales above $900 million and up to $2 billion, and (iv) no royalty owed for ann
- $2 billion — for annual U.S. net sales in excess of $2 billion. The Purchase and Sale Agreement may on
Filing Documents
- d20179d8k.htm (8-K) — 31KB
- g20179g1020041806390.jpg (GRAPHIC) — 3KB
- 0001193125-25-243039.txt ( ) — 152KB
- vrdn-20251017.xsd (EX-101.SCH) — 3KB
- vrdn-20251017_lab.xml (EX-101.LAB) — 18KB
- vrdn-20251017_pre.xml (EX-101.PRE) — 11KB
- d20179d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viridian Therapeutics, Inc. Date: October 20, 2025 By: /s/ Stephen Mahoney Stephen Mahoney President and Chief Executive Officer